Novel bimodal bifunctional ligands for radioimmunotherapy and targeted MRI

Bioconjugate Chemistry

Volumn 19, Issue 7, 2008, Pages 1439-1447

  Chong, Hyun Soon ^a,c   Song, Hyun A ^a   Ma, Xiang ^a   Milenic, Diane E ^b   Brady, Erik D ^b   Lim, Sooyoun ^a   Lee, Haisung ^a   Baidoo, Kwamena ^b   Cheng, Dengfeng ^a   Brechbiel, Martin W ^b  

^a Illinois Institute of Technology   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ILLINOIS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; GADOLINIUM COMPOUNDS; LIGANDS; MAGNETIC RESONANCE IMAGING; RADIATION; RADIOACTIVITY; REACTION INTERMEDIATES;

BIFUNCTIONAL LIGAND; CONTRAST ENHANCEMENT; IN-VITRO; IN-VIVO; LOW-RADIOACTIVITY; MACROCYCLIC MOIETY; RADIOACTIVITY LEVEL; RADIOIMMUNOTHERAPY; RELAXIVITY; SYNTHETIC METHODS;

MONOCLONAL ANTIBODIES;

BISMUTH DERIVATIVE; GADOLINIUM 153; LEAD 203; LIGAND; LUTETIUM 177; RADIOPHARMACEUTICAL AGENT; TRASTUZUMAB; YTTRIUM 90; [(4 (2 (BIS CARBOXYMETHYL AMINO) 3 (4 NITRO PHENYL) PROPYL) 7 CARBOXYMETHYL(1,4,7)TRIAZONAN 1 YL)ACETIC ACID]; [(4 (2 (BIS CARBOXYMETHYL AMINO) 3 (4 NITRO PHENYL) PROPYL) 7 CARBOXYMETHYL(1,4,7)TRIAZONAN 1 YL)ACETIC ACID] BISMUTH 205; [(4 (2 (BIS CARBOXYMETHYL AMINO) 3 (4 NITRO PHENYL) PROPYL) 7 CARBOXYMETHYL(1,4,7)TRIAZONAN 1 YL)ACETIC ACID] BISMUTH 206; [(4 (2 (BIS CARBOXYMETHYL AMINO) 3 (4 NITRO PHENYL) PROPYL) 7 CARBOXYMETHYL(1,4,7)TRIAZONAN 1 YL)ACETIC ACID] GADOLINIUM 153; [(4 (2 (BIS CARBOXYMETHYL AMINO) 3 (4 NITRO PHENYL) PROPYL) 7 CARBOXYMETHYL(1,4,7)TRIAZONAN 1 YL)ACETIC ACID] LEAD 203; [(4 (2 (BIS CARBOXYMETHYL AMINO) 3 (4 NITRO PHENYL) PROPYL) 7 CARBOXYMETHYL(1,4,7)TRIAZONAN 1 YL)ACETIC ACID] LUTETIUM 177; [(4 (2 (BIS CARBOXYMETHYL AMINO) 3 (4 NITRO PHENYL) PROPYL) 7 CARBOXYMETHYL(1,4,7)TRIAZONAN 1 YL)ACETIC ACID] YTTRIUM 90; [(4 CARBOXYMETHYL 7 (2 (CARBOXYMETHYL AMINO) 3 (4 NITRO PHENYL)PROPHYL) (1,4,7)TRIAZO NAN 1 YL)ACETIC ACID]; [(4 CARBOXYMETHYL 7 (2 (CARBOXYMETHYL AMINO) 3 (4 NITRO PHENYL)PROPHYL) (1,4,7)TRIAZO NAN 1 YL)ACETIC ACID]BISMUTH 205; [(4 CARBOXYMETHYL 7 (2 (CARBOXYMETHYL AMINO) 3 (4 NITRO PHENYL)PROPHYL) (1,4,7)TRIAZO NAN 1 YL)ACETIC ACID]BISMUTH 206; [(4 CARBOXYMETHYL 7 (2 (CARBOXYMETHYL AMINO) 3 (4 NITRO PHENYL)PROPHYL) (1,4,7)TRIAZO NAN 1 YL)ACETIC ACID]GADOLINIUM 153; [(4 CARBOXYMETHYL 7 (2 (CARBOXYMETHYL AMINO) 3 (4 NITRO PHENYL)PROPHYL) (1,4,7)TRIAZO NAN 1 YL)ACETIC ACID]LEAD 203; [(4 CARBOXYMETHYL 7 (2 (CARBOXYMETHYL AMINO) 3 (4 NITRO PHENYL)PROPHYL) (1,4,7)TRIAZO NAN 1 YL)ACETIC ACID]LUTETIUM 177; [(4 CARBOXYMETHYL 7 (2 (CARBOXYMETHYL AMINO) 3 (4 NITRO PHENYL)PROPHYL) (1,4,7)TRIAZO NAN 1 YL)ACETIC ACID]YTTRIUM 90;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA CLEARANCE; PURIFICATION; RADIOACTIVITY; RADIOIMMUNOTHERAPY;

MUS;

EID: 47749102922     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc800050x     Document Type: Article

References (27)

1. Knox, S. J., and Meredith, R. F. (2000) Clinical radioimmunotherapy. Semin. Radiat. Oncol. 10, 73-93.
2. Caravan, P., Ellison, J. J., McMurry, T. J., and Lauffer, R. B. (1999) Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem. Rev. 99, 2293-2352.
3. Yoneda, S., Emi, N., Fujita, Y., Ohmichi, M., Hirano, S., and Suzuki, K. T. (1995) Effects of gadolinium chloride on the rat lung following intratracheal instillation. Fundam. Appl. Toxicol. 28, 65-70.
4. McDevitt, M. R., Ma, D., Lai, L. T., Simon, J., Borchardt, P., Frank, R. K., Wu, K., Pellegrini, V., Curcio, M. J., Miederer, M., Bander, N. H., and Scheinberg, D. A. (2001) Tumor therapy with targeted atomic nanogenerators. Science 294, 1537-40.
5. Srivastava, S., and Dadachova, E. (2001) Recent advances in radionuclide therapy. Semin. Nucl. Med. 31, 330-41.
6. Milenic, D. E., Brady, E. D., and Brechbiel, M. W. (2004) Antibody-targeted radiation cancer therapy. Nat. Rev. Drug Discovery 3, 488-99.
7. Borghaei, H., and Schilder, R. J. (2004) Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Semin. Nucl. Med. 34 (S1), 4-9.
8. Jhanwar, Y. S., and Divgi, C. J. (2005) Current status of therapy of solid tumors. Nucl. Med. 46 (S1), 141S-50S.
9. 213Bi, and their decay chain related radionuclides for therapeutic applications. Chem. Rev. 101, 2019-36.
10. Lewis, M. R., Raubitschek, A., and Shively, J. E. (1994) A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. Bioconjugate Chem. 5, 565-76.
11. Chakrabarti, M. C., Le, N., Paik, C. H., De Graff, W. G., and Carrasquillo, J. A. (1996) Prevention of radiolysis of monoclonal antibody during labeling. J. Nucl. Med. 37, 1384-8.
12. Liu, S., and Edwards, D. S. (2001) Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjugate Chem. 12, 7-34.
13. Raymond, K. N., and Pierre, V. C. (2005) Next generation, high relaxivity gadolinum MRI agents. Biconjugate Chem. 16, 3-8.
14. Band, L., Bertini, I., and Luchinat, C. (1991) Nuclear and Electronic Relaxation, VCH, Weinheim.
15. Yoneda, S., Emi, N., Fujita, Y., Ohmichi, M., Hirano, S., and Suzuki, K. T. (1995) Effects of gadolinium chloride on the rat lung following intratracheal instillation. Fundam. Appl. Toxicol. 28, 65-70.
16. Chong, H. S., Garmestani, K., Milenic, D., and Brechbiel, M. W. (2002) Design, synthesis, and biological evaluation of novel macrocycles with pendant donor groups as radioimmunotherapy (RIT) agents. J. Med. Chem. 45, 3458-64.
17. Chong, H. S., Milenic, D. E., Garmestani, K., Brady, E. D., Arora, H., Pfiester, C., and Brechbiel, M. W. (2006) In vitro and in vivo evaluation of novel ligands for radioimmunotherapy. Nucl. Med. Biol. 33, 459-67.
18. Chong, H. S., Garmestani, K., Bryant, L. H., Jr., Milenic, D. E., Overstreet, T., Birch, N., Le, T., Brady, E. D., and Brechbiel, M. W. (2006) Synthesis and evaluation of novel macrocyclic and acyclic ligands as contrast enhancement agents for magnetic resonance imaging. J. Med. Chem. 49, 2055-62.
19. Chong, H. S., Song, H. A., Birch, N., Le, T., Lim, S., and. Ma, X. (2008) Efficient synthesis and evaluation of bimodal ligand NETA. Bioorg. Med. Chem. Lett. In Press.
20. Ameido, J. C., Jr., Bernard, P. J., and Fountain, M., Jr. (1999) A practical manufacturing synthesis of 1-(R)-hydroxymethyl-DTPA: An important intermediate in the synthesis of MRI contrast agents. Syn. Commun. 29, 2377-91.
21. Kim, W. D., Kiefer, G. E., Maton, F., McMillan, K., Muller, R. N., and Sherry, A. D. (1995) Relaxometry, luminescence measurements, electrophoresis, and animal biodistribution of lanthanide(III) complexes of some polyaza macrocyclic acetates containing pyridine. Inorg. Chem. 34, 2233-43.
22. Agus, D. B., Jr., Franklin, W., Garcia, M., and Ozols, R. F. (2000) HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin. Oncol. 27, 53-63.
23. Pietras, R. J., Pegram, M. D., Finn, R. S., Maneval, D. A., and Slamon, D. J. (1998) Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17, 2235-49.
24. Brady, E. D., Chong, H. S., Milenic, D. E., and Brechbiel, M. W. (2004) Development of a spectroscopy assay for bifunctional ligand-protein conjugates based on copper. Nucl. Med. Biol. 31, 795-802.
25. Lowry, O. H., Rosebrough, N. J., Rarr, A. L., and Randall, A. J. (1951) Protein measurement with the folin phenol reagent. J. Biol. Chem. 193, 265-75.
26. Chong, H. S., Ma, X., Le, T., Kwamena, B., Milenic, D. E., Brady, E. D., Song, H. A., and Brechbiel, M. W. (2008) Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy. J. Med. Chem. 51, 118-25.
27. Barge, A., Cravotto, G., Gianolio, E., and Fedeli, F. (2006) How to determine free Gd and free ligand in solution of Gd chelates. Contrast Med. Mol. Imaging 1, 184-8.